Aignostics is a global leader in the development of AI-powered precision diagnostics for pathology and is one of only 15 Germany-based companies to be named to the list.
The ranking was produced in collaboration with data platform Statista and recognizes 400 companies across 35 countries. Segmented into seven categories, including diagnostics, health records, medical management and telehealth, Newsweek recognized Aignostics as a leader in diagnostics. According to Newsweek, the ranking is also based on such factors as financial performance, traffic data for its websites and apps, and the impact of Aignostics’ product and the expertise of its leadership.
Aignostics launched in 2020 and focuses on pioneering digital pathology for research, clinical trials, companion diagnostics, and clinical routine. Its co-founding team consists of Prof. Frederick Klauschen, Prof. Klaus-Robert Müller, Viktor Matyas, and Dr. Maximilian Alber.
About the BIH Digital Health Accelerator Program:
The BIH Digital Health Accelerator (DHA) at Charité BIH Innovation funds, guides and supports Charité/BIH clinicians and researchers at all stages of project readiness to turn their concepts into digital health solutions for launch via spin-off or licensing. Supported projects develop software as a medical device or health technology solutions based on, e.g., 3D bio-/printing, AI/machine learning, augmented/virtual reality, sensors, and software. Solution classes include clinical decision support systems, in-silico and in-vitro diagnostics, digital therapeutics, digital solutions for drug development, and patientcentered applications. With a proven track record of over 50 projects, 10 spin-offs and one exit to date, the BIH DHA offers funding of up to 1M Euro per project, protected time, expert mentoring, and a dedicated Digital Labs co-working space to help innovation teams find their momentum and accelerate the development of their digital health solutions to benefit patients, healthcare systems, and society at large.